William Blair reaffirmed their outperform rating on shares of Context Therapeutics (NASDAQ:CNTX - Free Report) in a report released on Tuesday,RTT News reports. William Blair also issued estimates for Context Therapeutics' Q1 2026 earnings at ($0.08) EPS, Q2 2026 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.08) EPS and Q4 2026 earnings at ($0.07) EPS.
Other equities research analysts have also recently issued reports about the stock. Citizens Jmp raised shares of Context Therapeutics to a "strong-buy" rating in a research report on Wednesday, January 8th. JMP Securities assumed coverage on Context Therapeutics in a report on Wednesday, January 8th. They set an "outperform" rating and a $4.00 target price on the stock. HC Wainwright restated a "buy" rating and issued a $5.00 price target on shares of Context Therapeutics in a research note on Friday, March 21st. Finally, D. Boral Capital reissued a "buy" rating and issued a $9.00 price objective on shares of Context Therapeutics in a report on Tuesday, April 29th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Buy" and an average target price of $6.17.
Check Out Our Latest Report on CNTX
Context Therapeutics Price Performance
Shares of CNTX traded up $0.01 during midday trading on Tuesday, hitting $0.87. The stock had a trading volume of 30,000 shares, compared to its average volume of 300,208. The firm has a market cap of $78.01 million, a price-to-earnings ratio of -0.96 and a beta of 2.18. The company has a 50 day simple moving average of $0.78 and a two-hundred day simple moving average of $1.16. Context Therapeutics has a twelve month low of $0.55 and a twelve month high of $2.75.
Context Therapeutics (NASDAQ:CNTX - Get Free Report) last issued its quarterly earnings results on Thursday, March 20th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.01. Analysts forecast that Context Therapeutics will post -0.51 EPS for the current fiscal year.
Institutional Trading of Context Therapeutics
A number of hedge funds have recently modified their holdings of CNTX. MPM Bioimpact LLC bought a new position in Context Therapeutics in the 4th quarter valued at about $15,441,000. Franklin Resources Inc. lifted its holdings in Context Therapeutics by 115.9% during the 4th quarter. Franklin Resources Inc. now owns 4,003,380 shares of the company's stock worth $4,204,000 after purchasing an additional 2,149,392 shares during the last quarter. Allostery Investments LP bought a new stake in Context Therapeutics in the 4th quarter valued at $998,000. Blue Owl Capital Holdings LP increased its position in Context Therapeutics by 17.5% during the 4th quarter. Blue Owl Capital Holdings LP now owns 6,357,928 shares of the company's stock worth $6,676,000 after buying an additional 946,638 shares during the period. Finally, Renaissance Technologies LLC boosted its position in shares of Context Therapeutics by 412.8% in the fourth quarter. Renaissance Technologies LLC now owns 338,435 shares of the company's stock valued at $355,000 after acquiring an additional 272,435 shares during the period. Institutional investors and hedge funds own 14.03% of the company's stock.
Context Therapeutics Company Profile
(
Get Free Report)
Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
Recommended Stories

Before you consider Context Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Context Therapeutics wasn't on the list.
While Context Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.